complete systemic imaging (including brain MRI) before third-generation EGFR-TKI treatment;
received standard third-generation EGFR-TKI therapy (monotherapy or combined with brain radiotherapy);
willing to cooperate with the follow-up after third-generation EGFR-TKI treatment;
informed consent of the patient.
You may not be if
Multiple primary or metastatic tumors (except early skin cancer, cervical carcinoma in situ that has been treated radically, with no recurrence or progression for more than 5 years);
Pregnant or lactating women who, as judged by the investigator, were not candidates for brain MRI;
EGFR sensitive mutations were negative or EGFR mutation status was not detected.
Uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance.
Clareo Health | AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
